期刊文献+

原发性腹膜后肉瘤的外科治疗 被引量:1

Surgical treatment of primary retroperitoneal sarcoma
下载PDF
导出
摘要 目的 探讨原发性腹膜后肉瘤的外科治疗方法。方法 回顾性分析 1992年 1月~ 2 0 0 0年 12月收治的 63例原发性腹膜后肉瘤 (脂肪肉瘤和平滑肌肉瘤 )的治疗效果、预后因素等临床资料。结果 肿瘤全切除率为 88.2 % ,其中联合脏器切除为 2 1.6% ,无围手术期死亡。脂肪肉瘤的术后平均生存时间 3 6.5个月 ,平滑肌肉瘤为 2 7.6个月。高分化肿瘤术后平均生存时间 3 7.4个月 ,中低分化肿瘤仅 18.1个月 (P <0 .0 1)。 3 2例作再次手术 ,其中肿瘤完全切除率为 62 .5 % (2 0 /3 2 ) ,术后平均生存时间为 19.8个月 ,其中 2 8.1%术后病理类型发生变化。结论 手术切除整个肿瘤及侵及的周围脏器是治疗的最佳手段 ,对局部复发的肿瘤争取再次手术 ,肿瘤的分化程度及能否完整切除肿瘤是影响预后的主要因素。 Objective To study the surgical treatment of the primary retroperitioneal sarcoma(RPS). Methods The treatment and prognosis of 63 patients with primary retroperitoneal sarcomas (liposarcomas and leiomyosarcomas) from Jan 1992 to Dec 2000 were analyzed retrospectively. Results The rate of complete tumor resection was 88.2%, and concomitant resection of involved adjacent organs was 21.6%. There was no operation death. The median survival time(MST) in liposarcomas that for was 36.5months, and leiomyosarcomas was 27.6 months. The MST in highly differentiated tumor was 34.7 months,and that of intermiade and low differtiated tumors was 18.1months(P<0.01). Thirty two patients underwent re-operation after local recurrence, and complete resection of local recurrence was in 62.5% of patrents, and the median survival time was 19.8months,and decling of the recurrence tumor differentiation grade developed in 28.1% of the patients. Conclusions Complete resection of the tumor and relevant organs is the best way to treat RPS, and local recurrence of tumor should be reoperated. Tumor differentiation and recurrence may be the main influencial factors of prognosis.
出处 《中国普通外科杂志》 CAS CSCD 2003年第3期187-188,共2页 China Journal of General Surgery
关键词 腹膜后肿瘤/外科学 脂肪肉瘤/外科学 平滑肌肉瘤/外科学 RETROPERITIONEAL NOUPLASMS/surg LIPOSARCOMA/surg LEIOMYOSARCOMA/surg
  • 相关文献

参考文献4

二级参考文献14

共引文献55

同被引文献20

  • 1O'Brien CA, Kreso A, Dick JE. Cancer stem ceils in solid tumors : an overview [ J ]. Semin Radiat Oncol, 2009, 19 : 71-77. 被引量:1
  • 2Tan BT, Park CY, AiUes LE, et al. The cancer stem cell hypothesis: a work in progress [ J ]. Lab Invest, 2006, 86 : 1203-1207. 被引量:1
  • 3Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies[J]. Semin Cancer Biol, 1990, 1 : 199-206. 被引量:1
  • 4Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67 [ J ]. J Immunol, 1984, 133 : 1710-1715. 被引量:1
  • 5Jonat W, Arnold N. Is the Ki-67 labelling index ready for clinical use? [J]. Ann Oncol, 2011, 22: 500-502. 被引量:1
  • 6Reiffers J. The french comprehensive cancer centers in the french oncology landscape [ J ]. Bull Cancer, 2013, 100 : 611-617. 被引量:1
  • 7Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions [ J ]. Nat Rev Cancer, 2008, 8: 755-768. 被引量:1
  • 8Zhao P, Li Y, Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocareinoma[ J]. BMC Cancer, 2010, 10: 218. 被引量:1
  • 9Allred D, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis[ J]. Mod Pathol,1998, 11: 155-168. 被引量:1
  • 10Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies [ J]. Clin Cancer Res, 2004, 10: 184-190. 被引量:1

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部